One small-cap medical company I rarely see discussed here is Avita Medical ($RCEL).
The interesting part is that this isn’t some pre-revenue biotech hoping for approval someday. They already have FDA-approved technology being used in burns and trauma care, and they’re expanding the platform into broader wound applications.
The market basically punished the stock after reimbursement disruptions and slower-than-expected adoption, but revenue is still growing and the valuation now looks compressed compared to many med-tech peers.
Things I’m watching:
Whether cash burn drops over the next few quarters
Continued reimbursement stabilization
Adoption of RECELL GO and Cohealyx
Potential operating leverage if growth accelerates again
Still high risk, but definitely one of the more overlooked recovery/speculative med-tech stories I’ve researched lately.